SLC5A2 and polycystic ovary syndrome: Hence, the possible use of SGLT2 inhibitors in PCOS which, originated as molecules for the treatment of Diabetes Mellitus type 2,in addition to acting on glycemic control, have shown efficacy in treating excess body fat mass, LGCI and the consequent dysregulation of the production of major adipokines such as leptin, but especially in reducing oxidative stress, blood pressure and to have, therefore, a protective effect on the cardiovascular system.